Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including:
Contributions come from leading voices in the field, including: - Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School - Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics - Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences
Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews series, which features reviews published in Cell Press primary research and Trends reviews journals.
1. Cover image - p. Cover 2. Title page - p. Cover 3. Table of Contents - p. Cover 4. Copyright - p. Cover 5. About Cell Press - p. Cover 6. Contributors - p. Cover 7. Preface - p. Cover 8. Chapter 1. The Evolving War on Cancer - p. Cover 9. Chapter 2. Can We Deconstruct Cancer, One Patient at a Time? - p. G12 10. Chapter 3. The Genetic Basis for Cancer Treatment Decisions - p. G23 11. Chapter 4. Cancer Epigenetics: From Mechanism to Therapy - p. G45 12. Chapter 5. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases - p. G75 13. Chapter 6. Antibody-Based Immunotherapy of Cancer - p. G100 14. Chapter 7. Macrophage Regulation of Tumor Responses to Anticancer Therapies - p. G115 15. Chapter 8. Recombinant Viral Vaccines for Cancer - p. G131 16. Chapter 9. Dynamics of Targeted Cancer Therapy - p. G156 17. Chapter 10. Targeting Protein–Protein Interactions as an Anticancer Strategy - p. G171 18. Chapter 11. Targeting the RAS Pathway in Melanoma - p. G187 19. Chapter 12. Targeting Tumor Cell Motility as a Strategy against Invasion and Metastasis - p. G205 20. Chapter 13. The Valley of Death in Anticancer Drug Development: A Reassessment - p. G222 21. Chapter 14. Metformin and Cancer: From the Old Medicine Cabinet to Pharmacological Pitfalls and Prospects - p. G239 22. Chapter 15. Curing APL through PML/RARA Degradation by As2O3 - p. G261 23. Chapter 16. A Snapshot of Chemoresistance to PARP Inhibitors - p. G282 24. Index - p. G293
Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including:
Contributions come from leading voices in the field, including: - Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School - Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics - Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences
Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews series, which features reviews published in Cell Press primary research and Trends reviews journals.
1. Cover image - p. Cover 2. Title page - p. Cover 3. Table of Contents - p. Cover 4. Copyright - p. Cover 5. About Cell Press - p. Cover 6. Contributors - p. Cover 7. Preface - p. Cover 8. Chapter 1. The Evolving War on Cancer - p. Cover 9. Chapter 2. Can We Deconstruct Cancer, One Patient at a Time? - p. G12 10. Chapter 3. The Genetic Basis for Cancer Treatment Decisions - p. G23 11. Chapter 4. Cancer Epigenetics: From Mechanism to Therapy - p. G45 12. Chapter 5. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases - p. G75 13. Chapter 6. Antibody-Based Immunotherapy of Cancer - p. G100 14. Chapter 7. Macrophage Regulation of Tumor Responses to Anticancer Therapies - p. G115 15. Chapter 8. Recombinant Viral Vaccines for Cancer - p. G131 16. Chapter 9. Dynamics of Targeted Cancer Therapy - p. G156 17. Chapter 10. Targeting Protein–Protein Interactions as an Anticancer Strategy - p. G171 18. Chapter 11. Targeting the RAS Pathway in Melanoma - p. G187 19. Chapter 12. Targeting Tumor Cell Motility as a Strategy against Invasion and Metastasis - p. G205 20. Chapter 13. The Valley of Death in Anticancer Drug Development: A Reassessment - p. G222 21. Chapter 14. Metformin and Cancer: From the Old Medicine Cabinet to Pharmacological Pitfalls and Prospects - p. G239 22. Chapter 15. Curing APL through PML/RARA Degradation by As2O3 - p. G261 23. Chapter 16. A Snapshot of Chemoresistance to PARP Inhibitors - p. G282 24. Index - p. G293
